CD8A and neoplasm: In contrast, mice that received either SLA–OVA (adm) alone, or any of the archaeosome formulations, i.e., SLA–OVA (adm), SLA–OVA (enc), or MS–OVA (enc), in combination with CPIs had detectable OVA-CD8+ T cells in both the spleen and the tumor (Table 1), although no significant differences between groups was observed.